Medicine News and Research

RSS

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.

21 Oct 2010

Menopausal estrogen replacement therapy speeds growth of ovarian cancer

Estrogen therapy used by menopausal women causes a type of ovarian cancer to grow five times faster, according to a new study by researchers at the University of Colorado Cancer Center.

21 Oct 2010

Burn injuries in children show vitamin E depletion in fat tissues

Severe burn injuries in children have been shown to rapidly deplete the levels of vitamin E in their body's adipose, or fat tissues, a new clinical study has found.

21 Oct 2010

Kinemed updates translational biomarkers strategy at 2010 Conference in Boston

Marc K. Hellerstein, M.D., Ph.D. Co-Founder and Chief of SAB, Kinemed, Inc. presented an "Updated Strategy for Using Disease Predictive Translational Biomarkers in the Rapidly Advancing Field of Causal Pathway Measurements" at the 2010 Personalized and Translational Medicine Conference. In Boston, on September 20-21, 2010.

21 Oct 2010

Joint stem cell study to investigate multiple sclerosis

A $2.2 million project by Victorian and Californian researchers will assess whether stem cell therapies can be used to combat diseases such as Multiple Sclerosis and Type-1 diabetes, and help organ transplant recipients. Speaking at AusBiotech 2010 in Melbourne today, Innovation Minister Gavin Jennings said the Brumby Labor Government had contributed $575,505 to the project, the fifth to be funded through the $28 million Victoria–California Stem Cell Alliance which was established in 2008 under the Biotechnology Strategic Development Plan.

21 Oct 2010

NIH awards $7 million grant to provide sustained care for HIV-positive inmates

The University of Illinois at Chicago has received a $7 million grant from the National Institutes of Health to study effective ways to seek, test, and treat inmates with HIV.

21 Oct 2010

Z-Medica enters agreement with two Swedish medical device distributors for QuikClot products

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed exclusive distribution agreements with Vingmed AB and Mediplast AB, two leading Swedish medical device distributors, for distribution of its QuikClot line of hemostatic agents in Sweden, Denmark and Norway for the first time.

From Medica Corporation 21 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

A universal cancer treatment for a universal cancer marker

A latest study shows that a hormone receptor normally confined to the reproductive organs is found in malignant tumors in many parts of the body. Researchers from the Mt. Sinai School of Medicine in New York City explained that this may mean a new target for the early diagnosis and treatment of cancer. The study was published in the latest issue of The New England Journal of Medicine.

20 Oct 2010

Nightingale signs over 400 EMR seats in Canada during first half of fiscal 2011

Nightingale Informatix Corporation, an application service provider (ASP) of electronic medical record (EMR) software and related services today announced that during its fiscal 2011 second quarter ended September 30, it signed agreements to deploy its Nightingale On Demand EMR and practice management solution with healthcare providers across Canada, representing more than 200 seats (A "Seat" is defined as a paying healthcare provider using Nightingale's Electronic Medical Record).

20 Oct 2010

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.

20 Oct 2010

CRN reinforces importance of DHA before, during and after pregnancy

In response to a study regarding fish oil use during pregnancy published in the October 19 issue of the Journal of the American Medical Association (JAMA), the Council for Responsible Nutrition (CRN), the leading trade association for the dietary supplement industry, reminds pregnant and lactating women of the undisputed importance of consuming the recommended amounts of docosahexaenoic acid (DHA) throughout pregnancy.

20 Oct 2010

JIPH selected for inclusion in MEDLINE Indexing

Elsevier Middle East announces that the Journal of Infection and Public Health (JIPH) has been selected for inclusion in MEDLINE, the premier bibliographic database of the U.S. National Library of Medicine (NLM). Citations for articles indexed, the indexing terms and the abstract printed in the journal are now searchable using PubMed (http://www.pubmed.gov). Indexing using the US National Library of Medicine's (NLM) advanced MeSH terminology will be retroactive from Volume 1, Issue 1 (2008) of the journal.

20 Oct 2010

$More studies needed on bisphosphonates therapy and fracture risk$

More studies needed on bisphosphonates therapy and fracture risk

On October 13, the Food and Drug Administration published a warning to doctors and patients about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs called bisphosphonates. This warning was much awaited in the light of a report published in the American Journal of Bone and Mineral Research in September titled "Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research."

20 Oct 2010

Loyola University Chicago MNSON supports recommendations to advance nursing profession

Loyola University Chicago Marcella Niehoff School of Nursing (MNSON) supports the recommendations recently issued by The Robert Wood Johnson Foundation and the Institute of Medicine to advance the nursing profession in the United States.

20 Oct 2010

Prostate cancer can risk of colon cancer: Study

Men with prostate cancer should be especially diligent about having routine screening colonoscopies, results of a new study by gastroenterologists at the University at Buffalo indicate.

20 Oct 2010

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.

20 Oct 2010

Nitric oxide inhalation reduces pain in sickle cell disease patients

Inhaling nitric oxide appears to safely and effectively reduce pain crises in adults with sickle cell disease, researchers report.

20 Oct 2010

Study finds ketamine-propofol combination effective for pediatric procedural sedation

Procedural sedation and analgesia is an essential element of care for children requiring painful procedures in the emergency department. The practice of combining ketamine and propofol, two common medications used in emergency departments, has become more popular. However, until recently, it was unclear whether this practice was superior to the use of either agent alone, especially in children.

20 Oct 2010

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

Researchers at the Allen Institute for Brain Science have found that the same genes have different activity patterns in the brain in individuals with different genetic backgrounds. These findings may help to explain individual differences in the effectiveness and side-effect profiles of therapeutic drugs and thus have implications for personalized medicine. The study is available in this week's online early edition of the Proceedings of the National Academy of Sciences (www.pnas.org).

20 Oct 2010